. 2013 Sep 6;8(9):e73579. doi: 10.1371/journal.pone.0073579

Table 2. Number and percentage (95% CI) of indeterminate results, number of positive and interpretable results and positive sensitivity rates (percentage; 95% CI) of QuantiFERON® Gold in Tube (QFT-GIT) in pulmonary TB patients stratified by HIV status and disease localization.

Active Pulmonary TB patients	HIV-infected	HIV-uninfected	Total patientstested	p value; HIV-infected vs HIV-uninfected
	(N = 38)	(N = 58)	(N = 96)
N of indeterminate results	9	2	11
Percentage of indeterminate results (95% CI)	23.7 (11.4–40.2)	3.5 (0.9–11.9)	11.5 (5.9–19.6	0.006
N of positive results^(a)/N of interpretable results^(b)	26/29	53/56	79/85
Clinical sensitivity^(c) (%; 95% CI)	68.4 (51.4–82.5)	91.4 (81.1–96.3)	82.5 (73.2–89.3	0.0053
Laboratory sensitivity^(d) (%, 95% CI)	89.7 (72.2–97.8)	94.6 (85.1–98.2)	92.9 (83.8–96.6	0.4058

Footnotes: QFT-GIT: QuantiFERON® Gold in Tube; HIV: human immunodeficiency virus; TB: tuberculosis.

^(a)

QFT-GIT with specific antigen cut –off point: 0.35 IU/mL.

^(b)

QFT-GIT with PHA cut –off point: 0.50 IU/mL.

^(c)

Clinical sensitivity: overall sensitivity calculated on the total of patients tested (indeterminate results included as negative).

^(d)

Laboratory sensitivity: sensitivity calculated only on the interpretable results (indeterminate results excluded).